Following positive Phase IIb trial results, RH5.1/Matrix-M could be the first blood-stage malaria vaccine brought to market.
The RH5.1/Matrix-M blood-stage malaria vaccine shows promise as a crucial secondary defence against malaria, complementing ...
A recent study carried out by researchers in Burkina Faso and the UK, and published in The Lancet Infectious Diseases, has shown that the first blood-stage malaria vaccine, RH5.1/Matrix-M, is safe, ...